Photo: Global Health Policy Center


"TB is a major global health public health emergency. Although preventable and curable, it remains among the world's major killers of young adults.” --Dr. Gerald Friedland, Professor of Medicine and of Epidemiology, Yale School of Medicine

As of 2015, tuberculosis once again became the leading infectious killer worldwide. While the world has made considerable progress in tackling this disease, the global community is still struggling to prevent, diagnose, and treat this ancient scourge. Furthermore, much of the gains achieved are now threatened by the rapid rise of multidrug-resistant tuberculosis (MDR-TB). The U.S. Government has invested significant resources to combat TB, and in 2015, the White House released a national action plan to combat MDR-TB.

The CSIS Global Health Policy Center closely examines U.S., international, and multilateral approaches to combat global tuberculosis. We seek to build bipartisan consensus on ways U.S. leadership can support the global community’s efforts to address the complex challenges involved in strengthening country-level capacities to enhance TB prevention and care.

Our work focuses on:

  • Advances in new drugs, diagnostics, vaccines, and tools that enhance infection control, surveillance, and access and adherence to TB treatment.
  • Drug-resistant tuberculosis and broader issues of antimicrobial resistance.
  • In-depth country studies.
  • The role of the U.S., low and middle-income countries, and multilateral donors.